The Effect of Retrograde Autologous Priming on Transfusion Requirements After Cardiac Surgery
Red Blood Cell TransfusionThe TheRAPy vanguard trial is a multicentre, multiple period randomized, cluster crossover vanguard trial testing the feasibility of a full-scale trial to evaluate whether a centre-based policy of routine use of RAP versus a policy of crystalloid priming reduces RBC transfusion for patients undergoing cardiac surgery on cardiopulmonary bypass. It will also provide information about key parameters of the TheRAPy full-scale trial.
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
10 and up
Participation Criteria
Inclusion Criteria:
* Hospitals completing \>200 adult cardiac surgical cases a year; (ii) 95% of cardiovascular surgery group (i.e., cardiac anesthesiologists, surgeons, and perfusionists) agree to manage patients under both autologous priming policies as per their randomization schedule for the duration of the trial.
* All patients undergoing cardiac surgery on cardiopulmonary bypass at an enrolled site during the trial period will be included in data collection.
Exclusion Criteria:
* Complete \<=200 cardiac surgical cases.
* \<95% of their cardiovascular surgery group agrees to manage patients according to either of the two policies.
Study Location
Hamilton General Hospital
Hamilton General HospitalHamilton, Ontario
Canada
Contact Study Team
St. Boniface Hospital
St. Boniface HospitalWinnipeg, Manitoba
Canada
Contact Study Team
Mullein Thorliefson, Dr.
Centre Hospitalier de l'Université de Montréal (CHUM)
Centre Hospitalier de l'Université de Montréal (CHUM)Montreal, Quebec
Canada
Contact Study Team
Francois Martin Carrier, Dr.
Montreal Heart Institute
Montreal Heart InstituteMontreal, Quebec
Canada
Contact Study Team
- Study Sponsored By
- Population Health Research Institute
- Participants Required
- More Information
- Study ID:
NCT06230198